With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.112881-51-3,4′-(4-Pyridyl)-2,2′:6′,2”-terpyridine,as a common compound, the synthetic route is as follows.
Single crystals of 3 were prepared by adding 0.5 mmol (0.149 g) of zinc nitrate hexahydrate, 1mmol of sodium perchlorate (0.122 g) and 0.5mmol (0.156 g) of pyterpy to 20mL of distilled water. This mixture was transferred to a hydrothermal bomb and placed at 150 C for 48 h. The yellow crystals were obtained by cooling the bomb to room temperature for 12 h. The crystals were washed with methanol and air dried. m.p. > 300 C. Yield: 0.343 g (73%). IR (selected bands; in cm1): 623 (m), 791 (m), 1089 (vs), 1412(m), 1472 (m), 1599 (m), 3449 (b). Anal. calc for ZnC40H34N8Cl2O11: C, 51.14; H, 3.65; N, 11.94%. Found; C, 50.82; H, 3.68; N, 11.92%.
112881-51-3, 112881-51-3 4′-(4-Pyridyl)-2,2′:6′,2”-terpyridine 11438308, acatalyst-ligand compound, is more and more widely used in various.
Reference£º
Article; Mehrani, Azadeh; Morsali, Ali; Ebrahimpour, Parisa; Journal of Coordination Chemistry; vol. 66; 5; (2013); p. 856 – 867;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI